Head-to-head · Cost-Efficiency Index
LillyDirect Foundayo vs Next Vial
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
LillyDirect Foundayo
Patients who want an FDA-approved, manufacturer-direct oral GLP-1 rather than a compounded injectable.
Visit LillyDirect FoundayoNext Vial
Shoppers who want a named pharmacy partner and verified LegitScript status without a membership fee.
Visit Next VialThe verdict
LillyDirect Foundayo and Next Vial tie on the Cost-Efficiency Index at 63/100, so neither wins outright on the numbers. For most shoppers we'd start with LillyDirect Foundayo (ranked #196, a hair above #198) — Patients who want an FDA-approved, manufacturer-direct oral GLP-1 rather than a compounded injectable. But Next Vial is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs LillyDirect Foundayo.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | LillyDirect Foundayo | Next Vial |
|---|---|---|
| Cost-Efficiency Index | 63/100 | 63/100 |
| Semaglutide / mo | Not disclosed | $249/mo (all doses, compounded) |
| Tirzepatide / mo | Not disclosed | $249/mo (all doses, compounded) |
| Semaglutide / yr (modeled) | — | $2,988 |
| Tirzepatide / yr (modeled) | — | $2,988 |
| Coverage | All 50 states | 49 states |
| Oral / sublingual | Yes | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #196 | #198 |
LillyDirect Foundayo
63/100Where the value is
- First-party Eli Lilly program -- highest possible manufacturer authenticity
- FDA-approved branded drug (orforglipron), not an unapproved compounded formulation
- Published self-pay starting price ($149) via savings card
The tradeoffs
- Not semaglutide or tirzepatide -- a different molecule (orforglipron), so not directly comparable on this list
- The $149 price is tied to a specific Savings Card program with its own terms, not an unconditional list price
Next Vial
63/100Where the value is
- Names its compounding pharmacy partner explicitly (Manifest Pharmacy, Greer, SC)
- Genuine LegitScript verification link found in the footer
- Explicit 44-state coverage list published in the FAQ
The tradeoffs
- Starting price is blended/generic ($249.97/mo) and not broken out by drug or dose tier anywhere public
- No individual medical director named
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.